Gadoxetic acid-enhanced multiparametric magnetic resonance imaging for cirrhotic liver nodules during multistep hepatocarcinogenesis

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR1900026668

Enrollment

Unknown

Registered

2019-10-17

Start date

2015-07-01

Completion date

Unknown

Last updated

2019-10-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cirrhotic liver nodules

Interventions

Gold Standard:Composite reference standards of either histopathological examinations, including biopsy, hepatectomy and liver transplantation specimens, or imaging, including follow-up or at least 12

Index test:Gadoxetic&#32

acid-enhanced&#32

multiparametric&#32

magnetic&#32

resonance&#32

imaging&#32

Eligibility

Sex/Gender

All

Age

18 Years to 83 Years

Inclusion criteria

Inclusion criteria: (1) Aged >=18 years; (2) High risk for HCC (cirrhosis and/or chronic hepatitis B virus infection); (3) No previous treatment for the hepatic lesions.

Exclusion criteria

Exclusion criteria: (1) Patients with a prior history of HCC; (2) Patients with Child-Pugh class C diseases; (3) Patients with cirrhosis due to congestive hepatic fibrosis or vascular disorders; (4) Patients with previous antitumoral treatment; (5) Patients with any contraindication of EOB-MRI; (6) The MR image is of insufficient quality for analysis; (7) There was no conclusive pathologic result within 1 month or follow-up imaging at least 12 months after initial MR examination.

Design outcomes

Primary

Measure	Time frame
signal intensity;apparent diffusion coefficient;D;D;perfusion fraction;fat fraction;T2;	—

Countries

China

Contacts

Public ContactBin Song

West China Hospital, Sichuan University

anicesong@vip.sina.com+86 18980601592

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026